Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

In the treatment of newly diagnosed multiple myeloma (MM), carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the long-held cornerstone regimen of ...

ASH 2025 immunotherapy data highlight the importance of treatment sequencing, real-world outcomes in high-risk populations, and the growing need to define when therapy can be safely de-escalated or ...

In vivo CAR T-cell therapies showed promise, with significant developments in partnerships and financing, culminating in a breakthrough for relapsed/refractory multiple myeloma. Precision medicine in ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Myeloma care improving; Choline and exercise boost brain health; Guidance on ER vs urgent care use. Advances in multiple myeloma care now included improved drugs and diagnostics that extend survival ...

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...